Managed Healthcare Executive January 4, 2024
The 10 drugs selected by CMS for price negotiation are priced about three times higher in the United States than in other countries, finds a new study by the Commonwealth Fund.
In February 2024, the Centers for Medicare and Medicaid Services (CMS) will begin negotiations for the first 10 drugs selected under the 2022 Inflation Reduction Act (IRA). A new study finds that the list prices for the 10 selected drugs are about three times higher in the United States than in other countries. Even after rebates and discounts, prices are higher than other countries, with the exception of Janssen’s Xarelto (rivaroxaban), according to recently released paper from the Commonwealth Fund. They found that Switzerland has the second-highest prices for...
Today's Sponsors
Today's Sponsor